NY-DILIGENT
Diligent, a leading GRC SaaS company, today announced a first-of-its-kind Enterprise Risk Management (ERM) dashboard powered by industry-leading market data from Moody’s (NYSE: MCO), the leading source of relevant insights on exponential risk. The dashboard will help Chief Risk Officers, Chief Financial Officers, general counsel and other risk professionals monitor critical risk factors, aggregate findings and present a clear and comprehensive report to the board to drive informed decisions and long-term success for the organization.
The ERM dashboard complements the recent launch of Board Reporting for ERM from Diligent, which provides organizations with a clear and consistent view of their internal risk posture. Together, leaders can gain a comprehensive understanding of both internal and external risk to drive decision making.
“As a board member, the ability to gain a clear picture of risks — from ESG or operational risks to supplier and competitor risks, market fluctuations, and financial health – is enormously useful,” said Patricia Galloway, Board Director at Stantec and Chairman of Pegasus Global Holding, Inc. “To me, the ability for practitioners to easily collect and collate risk data, and then present it in a way that tells a clear story of an organization’s external risk footprint, complemented by internal risk data, is what really sets this apart.”
“We’re thrilled to join forces with Moody’s to help organizations gain greater transparency into their risk identification and mitigation efforts against a complex and fluid risk landscape,” said Brian Stafford, President and CEO of Diligent. “The dashboard will make it easier for CFOs, GCs and risk professionals to pre-emptively identify risks lurking in the market and value chain, gain clearer visibility into potential exposure to operational and financial risks; and improve board and executive communication with clear and concise reporting.”
Leveraging powerful proprietary data from Moody's along with the ability to add valuable internal risk data aggregated from Diligent, the ERM dashboard provides:
- A holistic view of external risk with access to Moody's data including credit risk assessments, supplier performance risks scores, credit sentiment scores and country risk index.
- Data-driven decision-making to pre-emptively identify risk and enhance oversight, leveraging insights from Moody's comprehensive data sets.
- Effortless reporting to the C-suite and board, streamlining communication and delivering clear and concise insights to foster proactive risk management strategies.
“Navigating exponential risk in today’s dynamic business landscape is a key priority for today’s business leaders,” said David Platt, Chief Strategic Development Officer at Moody’s. “The ERM dashboard combines Moody’s vast and proprietary data estate with Diligent’s advanced technology to provide a comprehensive view of risks, empowering leaders to make informed decisions that help decode risk and unlock opportunity.”
Visit us here to learn more about the ERM dashboard with Moody’s.
About Diligent
Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.
Follow Diligent on LinkedIn, X (Twitter) and Facebook.
About Moody’s Corporation
In a world shaped by increasingly interconnected risks, Moody’s (NYSE: MCO) data, insights, and innovative technologies help customers develop a holistic view of their world and unlock opportunities. With a rich history of experience in global markets and a diverse workforce of 15,000 across more than 40 countries, Moody’s gives customers the comprehensive perspective needed to act with confidence and thrive. Learn more at www.moodys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515779465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zayed Sustainability Prize Opens Global Call for Transformative Solutions10.2.2025 14:21:00 CET | Press release
The US $5.9 million fund empowers small and medium sized enterprises, nonprofits, and high schools to develop sustainable solutions and transform their communitiesAcross 6 key categories – Health, Food, Energy, Water, Climate Action and Global High Schools – winners will be recognised for their groundbreaking impact and receive the prestigious award The UAE’s Zayed Sustainability Prize, a portfolio entity of Erth Zayed Philanthropies which has impacted 400 million lives worldwide by advancing innovative solutions to pressing global challenges, has officially announced its call for submissions for 2026. Marking 17 years of continued support and empowerment for the next generation of sustainability champions, the Prize invites small to medium enterprises (SMEs), nonprofit organisations, and high schools to submit their projects in six distinct categories: Health, Food, Energy, Water, Climate Action, and Global High Schools. This press release features multimedia. View the full release he
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer10.2.2025 14:00:00 CET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly and Company to research and develop innovative treatments for various cancers. Under this new agreement, the parties will leverage AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly’s drug candidate programs and extensive expertise in drug development to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies. AdvanCell’s competitive advantage in technology development and the infrastructure it has built to accelerate early-stage clinical trials in Australia enables AdvanCell to rapidly develop and progress novel Pb-212-containing radiotherapeutics from discovery into clinical trials. “This collaboration with Lilly represents a significant milestone for AdvanCell, recognizi
Rochon Genova LLP: Did You Purchase Shares of Aphria Inc. (“Aphria”) After January 29, 2018 and Hold Them Until March 23, 2018 and/or December 3, 2018?10.2.2025 14:00:00 CET | Press release
A Settlement has been reached in the global class action (the “Class Action”) against Aphria and certain of its former officers and directors (“Individual Defendants”) announces Rochon Genova LLP. The Settlement requires Court approval at an upcoming hearing. The Class Action alleges that, between January 29, 2018 and December 3, 2018, Aphria and the Individual Defendants made public misrepresentations to the capital markets, including in an Aphria Prospectus Offering in June 2018, in connection with two significant international business acquisitions made by Aphria during 2018, namely: (i) Aphria’s acquisition of a company called Nuuvera Inc. which was publicly announced on January 29, 2018; and (ii) Aphria’s acquisition of a company called LATAM Holdings Inc. which was publicly announced on July 17, 2018. The Class Action alleges that the substantial drop in Aphria’s share price following certain public disclosures about Aphria’s business on March 22 and on December 3, 2018, amounted
PHC and CCRM Collaborate to Develop Primary T-Cell Expansion Culture Processesto Enhance Efficiency and Improve Cell Quality10.2.2025 06:00:00 CET | Press release
PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary T-cell(*1) expansion culture processes that will seek to accelerate the manufacturing of cell and gene therapy (CGT) products. This joint initiative will integrate “LiCellGrowTM(*2), PHC’s cell expansion system under development, with CCRM’s deep knowledge of regenerative medicine and biomanufacturing to establish new culture processes to improve cell culture efficiency and quality for CGTs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250209611769/en/ *For research purposes only. Anticipated visual image of LiCellGrow. All features subject to change. (Graphic: Business Wire) Primary T-cells are used in process development and manufacturing for CGTs, such as in CAR-T cell therapy.(*3) However, primary T-cells derived directly from patients often exhibit significant variability in growth rates and quality, ma
NTT DATA Unveils Global Insights on GenAI Adoption in Banking: Divergent Strategies for Boosting Productivity vs. Cutting Costs10.2.2025 05:00:00 CET | Press release
Research from NTT DATA finds that as GenAI adoption rises, new pressures on return of investment are at the forefront of the challenges facing the banking industry. NTT DATA, a global digital business and IT services leader, has today launched a new global research report uncovering the use of generative AI (GenAI) in the banking sector worldwide. The report, titled “Intelligent banking in the Age of AI,” has found that despite the growing adoption of GenAI technology in the banking industry, banks and financial institutions are split when it comes to outcome-based strategies – only half of banks (50%) see it as a tool for improving productivity and efficiency. Similarly, half (49%) believe it can be used for reducing operational IT spend. Transforming Banking Through GenAI GenAI is more disruptive than any previous advance in banking technology. It is less a question of if, but when banks embrace this technology, due to its transformative ability to embed intelligence at every layer o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom